Bold takeaway: IV iron may improve survival and raise hemoglobin for patients with iron-deficiency anemia who are hospitalized with acute bacterial infections — a finding that could shift how this treatment is viewed in complex cases.
Intravenous iron, traditionally used to treat severe iron-deficiency anemia, showed safety and potential benefit in a large study of 85,000+ hospitalized adults with both iron-deficiency anemia and an acute bacterial infection. The analysis found that patients treated with IV iron had better overall survival and higher hemoglobin levels than those who did not receive IV iron.
Haris Sohail, MD, the study’s lead author and a hematology-oncology fellow at Charleston Area Medical Center in West Virginia, emphasizes that while IV iron is standard for severe iron-deficiency anemia, its use alongside active bacterial infection has been controversial. Laboratory work has suggested that certain bacteria may multiply when iron is added, though this hasn’t been confirmed in humans. Consequently, guidelines have long advised against IV iron during active bacterial infections due to infection-worsening concerns.
The researchers drew on a large, de-identified US database spanning 2000–2024, including adults 18 and older with iron-deficiency anemia hospitalized for an acute bacterial infection. The 85,000+ patient cohort encompassed the five most common acute infections treated in US hospitals: pneumonia (over 27,000), urinary tract infections (over 23,000), MRSA bacteremia (over 15,000), cellulitis (over 13,000), and colitis/inflammation of the colon (over 7,000), plus 143 meningitis cases. Outcomes were compared between those who received IV iron and those who did not, focusing on 14- and 90-day mortality, length of hospital stay, and hemoglobin changes 60–90 days post-treatment.
Across infections other than meningitis, IV iron recipients were statistically less likely to die within 14 or 90 days and experienced larger hemoglobin increases than untreated patients. In meningitis, IV iron did not improve survival, though it did not worsen outcomes.
The most pronounced survival benefits appeared in pneumonia, MRSA bacteremia, and colitis, according to Dr. Sohail. Those who received IV iron did stay in the hospital a bit longer — about four to six hours on average — but this small difference is not considered clinically meaningful.
Dr. Sohail notes the meningitis subgroup’s small size likely contributed to non-significant results there. Because this study analyzed historical records, it can demonstrate association but not causation. Limitations include the lack of granular data on specific bacteria or iron dosing, and the findings are most applicable to hospitalized patients with both iron-deficiency anemia and an active bacterial infection.
“These findings support considering IV iron as a safe additional therapy for patients hospitalized with both iron-deficiency anemia and an acute bacterial infection,” Dr. Sohail states. A randomized controlled trial would be the next step to confirm these observations.
Dr. Sohail and colleagues plan to present these results on Sunday, December 7, 2025, at 3:25 p.m. Eastern time during the plenary scientific session at the Orange County Convention Center.
What do you think about expanding IV iron use in complex infections? Do the potential survival benefits outweigh the theoretical infection risks, or should guidelines remain conservative until randomized trials confirm causation? Share your perspective in the comments.
